Estados Unidos - inglês - NLM (National Library of Medicine)

a-s medication solutions - betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - topical corticosteroids are indicated for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses. topical corticosteroids are contraindicated in those patients with a history of hypersensitivity to any of the components of the preparation.

Estados Unidos - inglês - NLM (National Library of Medicine)

american regent, inc. - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - when oral therapy is not feasible, the intramuscular use of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency.  synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. gastrointesti

Estados Unidos - inglês - NLM (National Library of Medicine)

american regent, inc. - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - when oral therapy is not feasible, the intramuscular use of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency.  synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. gastrointesti

Estados Unidos - inglês - NLM (National Library of Medicine)

asclemed usa, inc. - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - when oral therapy is not feasible, the intramuscular use of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency.  synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance.

Estados Unidos - inglês - NLM (National Library of Medicine)

oaklock, llc - betamethasone acetate (unii: ti05ao53l7) (betamethasone - unii:9842x06q6m), betamethasone sodium phosphate (unii: 7bk02scl3w) (betamethasone - unii:9842x06q6m) - betamethasone acetate 3 mg in 1 ml - when oral therapy is not feasible, the intramuscular use of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as follows: allergic states control of severe or incapacitating allergic conditions intractable to adequate trials of conventional treatment in asthma, atopic dermatitis, contact dermatitis, drug hypersensitivity reactions, perennial or seasonal allergic rhinitis, serum sickness, transfusion reactions. dermatologic diseases bullous dermatitis herpetiformis, exfoliative erythroderma, mycosis fungoides, pemphigus, severe erythema multiforme (stevens-johnson syndrome). endocrine disorders congenital adrenal hyperplasia, hypercalcemia associated with cancer, nonsuppurative thyroiditis. hydrocortisone or cortisone is the drug of choice in primary or secondary adrenocortical insufficiency. synthetic analogs may be used in conjunction with mineralocorticoids where applicable; in infancy mineralocorticoid supplementation is of particular importance. gastrointestinal diseases to tide the patient over a critical period of the disease in regional enteritis and ulcerative colitis. hematologic disorders acquired (autoimmune) hemolytic anemia, diamond-blackfan anemia, pure red cell aplasia, selected cases of secondary thrombocytopenia. miscellaneous trichinosis with neurologic or myocardial involvement, tuberculous meningitis with subarachnoid block or impending block when used with appropriate antituberculous chemotherapy. neoplastic diseases for palliative management of leukemias and lymphomas. nervous system acute exacerbations of multiple sclerosis; cerebral edema associated with primary or metastatic brain tumor or craniotomy. ophthalmic diseases sympathetic ophthalmia, temporal arteritis, uveitis and ocular inflammatory conditions unresponsive to topical corticosteroids. renal diseases to induce diuresis or remission of proteinuria in idiopathic nephrotic syndrome or that due to lupus erythematosus. respiratory diseases berylliosis, fulminating or disseminated pulmonary tuberculosis when used concurrently with appropriate antituberculous chemotherapy, idiopathic eosinophilic pneumonias, symptomatic sarcoidosis. rheumatic disorders as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis; acute rheumatic carditis; ankylosing spondylitis; psoriatic arthritis; rheumatoid arthritis, including juvenile rheumatoid arthritis (selected cases may require low-dose maintenance therapy). for the treatment of dermatomyositis, polymyositis, and systemic lupus erythematosus. the intra-articular or soft tissue administration of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in acute gouty arthritis, acute and subacute bursitis, acute nonspecific tenosynovitis, epicondylitis, rheumatoid arthritis, synovitis of osteoarthritis. the intralesional administration of betamethasone sodium phosphate and betamethasone acetate injectable suspension is indicated for alopecia areata; discoid lupus erythematosus; keloids; localized hypertrophic, infiltrated, inflammatory lesions of granuloma annulare, lichen planus, lichen simplex chronicus (neurodermatitis), and psoriatic plaques; necrobiosis lipoidica diabeticorum. betamethasone sodium phosphate and betamethasone acetate injectable suspension may also be useful in cystic tumors of an aponeurosis or tendon (ganglia). betamethasone sodium phosphate and betamethasone acetate injectable suspension is contraindicated in patients who are hypersensitive to any components of this product. intramuscular corticosteroid preparations are contraindicated for idiopathic thrombocytopenic purpura.

Estados Unidos - inglês - NLM (National Library of Medicine)

vedco - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m), clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65) - gentamicin 3 mg in 1 g - indications :  gentamicin-betamethasone-clotrimazole ointment is indicated for the treatment of canine acute and chronic otitis externa associated with yeast (malassezia pachydermatis , formerly pityrosporum canis ) and/or bacteria susceptible to gentamicin. contraindications : if hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. do not use in dogs with known perforation of eardrums.

Estados Unidos - inglês - NLM (National Library of Medicine)

clipper distribution company llc - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m), clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65) - indications :  gentamicin-betamethasone-clotrimazole ointment is indicated for the treatment of canine acute and chronic otitis externa associated with yeast (malassezia pachydermatis , formerly pityrosporum canis ) and/or bacteria susceptible to gentamicin. contraindications : if hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. do not use in dogs with known perforation of eardrums.

Estados Unidos - inglês - NLM (National Library of Medicine)

mwi - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m), clotrimazole (unii: g07gz97h65) (clotrimazole - unii:g07gz97h65) - indications :  gentamicin-betamethasone-clotrimazole ointment is indicated for the treatment of canine acute and chronic otitis externa associated with yeast (malassezia pachydermatis , formerly pityrosporum canis ) and/or bacteria susceptible to gentamicin. contraindications : if hypersensitivity to any of the components occurs, treatment should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. do not use in dogs with known perforation of eardrums.

Estados Unidos - inglês - NLM (National Library of Medicine)

vedco - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 3 mg in 1 ml - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.

Estados Unidos - inglês - NLM (National Library of Medicine)

mwi - gentamicin sulfate (unii: 8x7386qrlv) (gentamicin - unii:t6z9v48ikg), betamethasone valerate (unii: 9ifa5xm7r2) (betamethasone - unii:9842x06q6m) - gentamicin 3 mg in 1 ml - indications: gentamicin sulfate with betamethasone valerate otic solution is indicated for the treatment of acute and chronic canine otitis externa and canine and feline superficial infected lesions caused by bacteria sensitive to gentamicin. contraindications: if hypersensitivity of any of the components occurs, treatment with this product should be discontinued and appropriate therapy instituted. concomitant use of drugs known to induce ototoxicity should be avoided. this preparation should not be used in conditions where corticosteroids are contraindicated. do not administer parenteral corticosteroids during treatment with gentamicin sulfate with betamethasone valerate otic solution.